Characteristics and treatment outcomes of patients treated with HCT
| Number of patients transplanted . | 17 . |
|---|---|
| Donor, n (%) | |
| Matched sibling | 12 (70) |
| Matched unrelated | 4 (24) |
| Mismatched unrelated | 1 (6) |
| Cell type, n (%) | |
| BM | 3 (18) |
| Mobilized PB HSCs | 14 (82) |
| Conditioning, n (%) | |
| Myeloablative | 8 (47) |
| Reduced intensity | 9 (53) |
| Clinical status at transplant, n (%) | |
| CR1 | 8 (47) |
| CR2 | 2 (12) |
| cMPN | 7 (41) |
| Primary engraftment, n (%) | 16 (94) |
| Days to ANC .5 x 109/L (median), n | 19 |
| Days to PLT count 20 x 109/L (median), n | 11 |
| Acute GVHD, n (%) | |
| None | 3 (18) |
| Grade 1-2 | 11 (65) |
| Grade 3-4 | 2 (12) |
| Not applicable | 1 (6) |
| Chronic GVHD, n (%) | |
| None/limited | 4 (24) |
| Extensive | 9 (53) |
| Not applicable | 4 (24) |
| Status at last follow-up, n (%) | |
| Alive | 5 (29) |
| Dead | 12 (71) |
| Cause of death, n (%) | |
| Relapse | 4 (33) |
| Infection | 6 (50) |
| Regimen-related toxicity | 2 (17) |
| Number of patients transplanted . | 17 . |
|---|---|
| Donor, n (%) | |
| Matched sibling | 12 (70) |
| Matched unrelated | 4 (24) |
| Mismatched unrelated | 1 (6) |
| Cell type, n (%) | |
| BM | 3 (18) |
| Mobilized PB HSCs | 14 (82) |
| Conditioning, n (%) | |
| Myeloablative | 8 (47) |
| Reduced intensity | 9 (53) |
| Clinical status at transplant, n (%) | |
| CR1 | 8 (47) |
| CR2 | 2 (12) |
| cMPN | 7 (41) |
| Primary engraftment, n (%) | 16 (94) |
| Days to ANC .5 x 109/L (median), n | 19 |
| Days to PLT count 20 x 109/L (median), n | 11 |
| Acute GVHD, n (%) | |
| None | 3 (18) |
| Grade 1-2 | 11 (65) |
| Grade 3-4 | 2 (12) |
| Not applicable | 1 (6) |
| Chronic GVHD, n (%) | |
| None/limited | 4 (24) |
| Extensive | 9 (53) |
| Not applicable | 4 (24) |
| Status at last follow-up, n (%) | |
| Alive | 5 (29) |
| Dead | 12 (71) |
| Cause of death, n (%) | |
| Relapse | 4 (33) |
| Infection | 6 (50) |
| Regimen-related toxicity | 2 (17) |
GVHD, graft-versus-host disease.